Tradewinds Capital Management’s GT Biopharma GTBP Stock Holding History

Tradewinds Capital Management’s Portfolio GTBP Stock Details GTBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1	Closed	–	–	771
2021 Q2	$0	Hold	1	–	–	﹤0.01%	786
2021 Q1	$0	Buy	+1	New	+$175	﹤0.01%	760

Other funds holding GTBP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

SCP

Silverleafe Capital Partners Germantown, Tennessee $367M AUM 37.49% 1-Year Est. Return

Tradewinds Capital Management's GTBP Position: Q3 2021 in Review

Tradewinds Capital Management sold out of GT Biopharma (GTBP) in Q3 2021, closing a stake of 1 share.

Tradewinds Capital Management first reported a position in GTBP in Q1 2021 and held it in 2 quarters. The position peaked at $0 in Q2 2021. 53 funds tracked by Wall St. Rank hold GTBP as of Q3 2021.

Tradewinds Capital Management reported no remaining GT Biopharma position as of Q3 2021 after selling out during the quarter.
Tradewinds Capital Management sold 1 GT Biopharma share in Q3 2021.
Tradewinds Capital Management first reported a position in GT Biopharma in Q1 2021 and held it in 2 quarters.
Tradewinds Capital Management's GT Biopharma position peaked at $0 in Q2 2021.
53 funds tracked by Wall St. Rank held GT Biopharma as of Q3 2021.

Based on Tradewinds Capital Management's 13F filing for Q3 2021, filed 4 Nov 2021.